title: An inactivated yellow fever 17DD vaccine cultivated in Vero cell cultures.
abstract: Yellow fever is an acute infectious disease caused by prototype virus of the genus Flavivirus. It is endemic in Africa and South America where it represents a serious public health problem causing epidemics of hemorrhagic fever with mortality rates ranging from 20% to 50%. There is no available antiviral therapy and vaccination is the primary method of disease control. Although the attenuated vaccines for yellow fever show safety and efficacy it became necessary to develop a new yellow fever vaccine due to the occurrence of rare serious adverse events, which include visceral and neurotropic diseases. The new inactivated vaccine should be safer and effective as the existing attenuated one. In the present study, the immunogenicity of an inactivated 17DD vaccine in C57BL/6 mice was evaluated. The yellow fever virus was produced by cultivation of Vero cells in bioreactors, inactivated with β-propiolactone, and adsorbed to aluminum hydroxide (alum). Mice were inoculated with inactivated 17DD vaccine containing alum adjuvant and followed by intracerebral challenge with 17DD virus. The results showed that animals receiving 3 doses of the inactivated vaccine (2 μg/dose) with alum adjuvant had neutralizing antibody titers above the cut-off of PRNT50 (Plaque Reduction Neutralization Test). In addition, animals immunized with inactivated vaccine showed survival rate of 100% after the challenge as well as animals immunized with commercial attenuated 17DD vaccine.
authors: Oswaldo Cruz Foundation (FIOCRUZ), Bio-Manguinhos, Avenida Brasil 4365, 21045-900, Rio de Janeiro, RJ, Brazil.
authors: Renata C
authors: RC
authors: Pereira
authors: Oswaldo Cruz Foundation (FIOCRUZ), Bio-Manguinhos, Avenida Brasil 4365, 21045-900, Rio de Janeiro, RJ, Brazil.
authors: Andrea N M R
authors: AN
authors: Silva
authors: Oswaldo Cruz Foundation (FIOCRUZ), Bio-Manguinhos, Avenida Brasil 4365, 21045-900, Rio de Janeiro, RJ, Brazil.
authors: Marta Cristina O
authors: MC
authors: Souza
authors: Oswaldo Cruz Foundation (FIOCRUZ), Bio-Manguinhos, Avenida Brasil 4365, 21045-900, Rio de Janeiro, RJ, Brazil.
authors: Marlon V
authors: MV
authors: Silva
authors: Oswaldo Cruz Foundation (FIOCRUZ), Bio-Manguinhos, Avenida Brasil 4365, 21045-900, Rio de Janeiro, RJ, Brazil.
authors: Patrícia P C C
authors: PP
authors: Neves
authors: Oswaldo Cruz Foundation (FIOCRUZ), Bio-Manguinhos, Avenida Brasil 4365, 21045-900, Rio de Janeiro, RJ, Brazil.
authors: Andrea A M V
authors: AA
authors: Silva
authors: Oswaldo Cruz Foundation (FIOCRUZ), Bio-Manguinhos, Avenida Brasil 4365, 21045-900, Rio de Janeiro, RJ, Brazil.
authors: Denise D C S
authors: DD
authors: Matos
authors: Oswaldo Cruz Foundation (FIOCRUZ), Bio-Manguinhos, Avenida Brasil 4365, 21045-900, Rio de Janeiro, RJ, Brazil.
authors: Miguel A O
authors: MA
authors: Herrera
authors: Oswaldo Cruz Foundation (FIOCRUZ), Bio-Manguinhos, Avenida Brasil 4365, 21045-900, Rio de Janeiro, RJ, Brazil.
authors: Anna M Y
authors: AM
authors: Yamamura
authors: Oswaldo Cruz Foundation (FIOCRUZ), Bio-Manguinhos, Avenida Brasil 4365, 21045-900, Rio de Janeiro, RJ, Brazil.
authors: Marcos S
authors: MS
authors: Freire
authors: Oswaldo Cruz Foundation (FIOCRUZ), Bio-Manguinhos, Avenida Brasil 4365, 21045-900, Rio de Janeiro, RJ, Brazil. Electronic address: lgaspar@bio.fiocruz.br.
authors: Luciane P
authors: LP
authors: Gaspar
authors: Oswaldo Cruz Foundation (FIOCRUZ), Bio-Manguinhos, Avenida Brasil 4365, 21045-900, Rio de Janeiro, RJ, Brazil.
authors: Elena
authors: E
authors: Caride
mesh_terms: D000818:Animals; D057134:Antibodies, Neutralizing / Q000096:biosynthesis / Q000097:blood* / Q000276:immunology; D000914:Antibodies, Viral / Q000096:biosynthesis / Q000097:blood* / Q000276:immunology; D019149:Bioreactors / Q000821:virology; D002522:Chlorocebus aethiops; D004202:Disinfectants / Q000494:pharmacology; D056724:Immunity, Humoral; D007115:Immunization Schedule; D008810:Mice, Inbred C57BL; D009500:Neutralization Tests; D011420:Propiolactone / Q000494:pharmacology; D016019:Survival Analysis; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000276:immunology; D014709:Vero Cells; D014776:Virus Cultivation; D015004:Yellow Fever / Q000517:prevention & control*; D022341:Yellow Fever Vaccine / Q000008:administration & dosage / Q000276:immunology*; D015005:Yellow fever virus / Q000254:growth & development* / Q000276:immunology / Q000302:isolation & purification / Q000472:pathogenicity
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D004202:Disinfectants; D015164:Vaccines, Inactivated; D022341:Yellow Fever Vaccine; D011420:Propiolactone
keywords: Inactivated vaccine; Protective response; Yellow fever